AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32539711 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital programme
Number of subjects: 67
Study 32539711 — intervention group
Group type: COMPARATOR
Intervention: Paper booklet
Number of subjects: 67
Study 32539719 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 0
Study 32539729 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn Behavioral Observation (NBO)
Number of subjects: 196
Study 32539729 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (comparison group)
Number of subjects: 196
Study 32539738 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic analysis of drinking task
Number of subjects: 56
Study 32539744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of 0.5 mg ranibizumab under '1 + PRN' regimen
Number of subjects: 69
Study 32539773 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS and SERS spectroscopies
Number of subjects: 0
Study 32539773 — intervention group
Group type: COMPARATOR
Intervention: Liquid Chromatography-Mass Spectrometry (LC-MS)
Number of subjects: 0
Study 32539794 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7 g/day of DHA
Number of subjects: 122
Study 32539794 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.7 g/day of EPA
Number of subjects: 122
Study 32539794 — intervention group
Group type: COMPARATOR
Intervention: 3 g/day of corn oil (control)
Number of subjects: 122
Study 32539794 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of participants with neutral TG responsiveness
Number of subjects: 122
Study 32540647 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous motion monitoring based localization (Calypso) with initial localization, CBCT, pre-treatment motion correction by kV-imaging, and gating during irradiation (strategy A)
Number of subjects: 22
Study 32540647 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-gated treatments (strategy B)
Number of subjects: 22
Study 32540647 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-gated and single image-guided (CBCT) localization (strategy C)
Number of subjects: 22
Study 32540838 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-Exercise and Multiple Sclerosis (TEAMS) intervention, 12-week complementary and alternative medicine (CAM) intervention with 20 sessions of synchronous training sessions of dual tasking, yoga, and Pilates exercises.
Number of subjects: 759
Study 32540838 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleassessment measures including resting blood pressure and heart rate, grip strength, Five Times Sit to Stand, Timed Up & Go, and the Berg Balance Scale.
Number of subjects: 759
Study 32540838 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining period of 9 months of continued exercise as instructed.
Number of subjects: 759
Study 32540851 — intervention group
Group type: EXPERIMENTAL
Intervention: FSP neoantigen vaccination
Number of subjects: 0
Study 32540858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab 0.5, 2, 5 or 10 mg/kg every 2 weeks; 2 or 5 mg/kg every 2 or 3 weeks; or 200 mg every 3 weeks (Phase IA)
Number of subjects: 451
Study 32540858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab 5 mg/kg every 3 weeks (Phase IB)
Number of subjects: 451
Study 32540858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab (all doses)
Number of subjects: 451
Study 32540858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks
Number of subjects: 451
Study 32541189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam
Number of subjects: 906
Study 32541189 — intervention group
Group type: EXPERIMENTAL
Intervention: Galilei
Number of subjects: 906
Study 32541189 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 906
Study 32541292 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine 1.3% (266 mg, 20 mL) and bupivacaine hydrochloride 0.25% (52 mg, 20 mL)
Number of subjects: 30
Study 32541385 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with HIV on ART
Number of subjects: 34
Study 32541385 — intervention group
Group type: COMPARATOR
Intervention: Women without HIV
Number of subjects: 34
Study 32541391 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical risk model based on 6 clinical predictors (surgical procedure, younger age, physical health, mental health, preoperative pain in the surgical field, preoperative pain in another area)
Number of subjects: 1088
Study 32541565 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceased donor uterus transplant (DD UTx)
Number of subjects: 10
Study 32541565 — intervention group
Group type: COMPARATOR
Intervention: Live-donor uterus transplant (not detailed in the abstract)
Number of subjects: 10
Study 32542023 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPIs)
Number of subjects: 703
Study 32542023 — intervention group
Group type: EXPERIMENTAL
Intervention: High PPI dose (>20 mg omeprazole equivalents/day)
Number of subjects: 703
Study 32542023 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PPI dose
Number of subjects: 703
Study 32542023 — intervention group
Group type: COMPARATOR
Intervention: No PPIs
Number of subjects: 703
Study 32542089 — intervention group
Group type: EXPERIMENTAL
Intervention: TURBT
Number of subjects: 983
Study 32542216 — intervention group
Group type: EXPERIMENTAL
Intervention: Massive PE
Number of subjects: 1188
Study 32542216 — intervention group
Group type: EXPERIMENTAL
Intervention: Submassive PE
Number of subjects: 1188
Study 32542216 — intervention group
Group type: EXPERIMENTAL
Intervention: NRVD PE
Number of subjects: 1188
Study 32542216 — intervention group
Group type: EXPERIMENTAL
Intervention: SSO PE
Number of subjects: 1188
Study 32542466 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg daily for 8 weeks
Number of subjects: 32
Study 32542468 — intervention group
Group type: EXPERIMENTAL
Intervention: Flortaucipir PET (injection of ~370 mBq flortaucipir, 20-min PET scan starting 80 min post-injection)
Number of subjects: 3
Study 32542468 — intervention group
Group type: EXPERIMENTAL
Intervention: Flortaucipir PET
Number of subjects: 3
Study 32542497 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes Decision Aid
Number of subjects: 0
Study 32542497 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 32542577 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy initiated prior to sampling
Number of subjects: 56
Study 32542577 — intervention group
Group type: COMPARATOR
Intervention: No prior antibiotic exposure
Number of subjects: 56
Study 32542577 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 56
Study 32542853 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualiveen
Number of subjects: 189
Study 32542853 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-Qualiveen
Number of subjects: 189
Study 32542853 — intervention group
Group type: COMPARATOR
Intervention: ICIQ-SF
Number of subjects: 189
Study 32542873 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of antidepressants
Number of subjects: 63999
Study 32542873 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 63999
Study 32542873 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine-type antidepressants
Number of subjects: 63999
Study 32542873 — intervention group
Group type: EXPERIMENTAL
Intervention: Other or mixed antidepressants
Number of subjects: 63999
Study 32542890 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne viral source strength measurement
Number of subjects: 0
Study 32542890 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor CO2 levels measurement
Number of subjects: 0
Study 32542985 — intervention group
Group type: EXPERIMENTAL
Intervention: Klinefelter syndrome (KS) group
Number of subjects: 50
Study 32542985 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 32544032 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired reservoir strain (≤22%)
Number of subjects: 321
Study 32544032 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired conduit strain (≤10%)
Number of subjects: 321
Study 32544032 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 321
Study 32544223 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplant recipients (RTRs)
Number of subjects: 247
Study 32544223 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal hrHPV positive RTRs
Number of subjects: 247
Study 32544223 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for anal HSIL in RTRs
Number of subjects: 247
Study 32544223 — intervention group
Group type: COMPARATOR
Intervention: Immunocompetent controls
Number of subjects: 247
Study 32544297 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP prophylaxis 50 IU/kg every fourth day (Q4D)
Number of subjects: 186
Study 32544297 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP prophylaxis 75 IU/kg once weekly (Q7D)
Number of subjects: 186
Study 32544297 — intervention group
Group type: EXPERIMENTAL
Intervention: N8-GP (all treatment arms)
Number of subjects: 186
Study 32544491 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 3 polygraphy using Somnolter
Number of subjects: 78
Study 32545531 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat intake
Number of subjects: 0
Study 32545531 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain intake
Number of subjects: 0
Study 32545856 — intervention group
Group type: EXPERIMENTAL
Intervention: ILTHPI (Intraluminal Therapy for H. pylori Infection)
Number of subjects: 324
Study 32545856 — intervention group
Group type: COMPARATOR
Intervention: Normal acidity (pH < 4.0)
Number of subjects: 324
Study 32545856 — intervention group
Group type: COMPARATOR
Intervention: Low-level hypoacidity (pH 4.0-5.5)
Number of subjects: 324
Study 32545856 — intervention group
Group type: COMPARATOR
Intervention: High-level hypoacidity (pH ≥ 6.0)
Number of subjects: 324
Study 32546071 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (9-28-112 μg/day) in a 70-day cycle 1 and an optional 28-day cycle 2
Number of subjects: 41
Study 32546071 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (9-28-112 μg/day)
Number of subjects: 41
Study 32546136 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic analysis, gut microbiota characterization, and behavioral phenotyping using the Recovery Record app for 30 days.
Number of subjects: 1000
Study 32546275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary linoleic acid (LA)
Number of subjects: 633
Study 32546275 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating linoleic acid (LA)
Number of subjects: 633
Study 32546275 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary linoleic acid (LA)
Number of subjects: 633
Study 32546636 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm coiling for unruptured aneurysms
Number of subjects: 1140
Study 32546636 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm coiling for ruptured aneurysms
Number of subjects: 1140
Study 32546636 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete aneurysm occlusion after initial treatment
Number of subjects: 1140
Study 32546636 — intervention group
Group type: COMPARATOR
Intervention: Complete aneurysm occlusion after initial treatment
Number of subjects: 1140
Study 32546636 — intervention group
Group type: EXPERIMENTAL
Intervention: Dome-to-neck ratio with rebleeding
Number of subjects: 1140
Study 32546636 — intervention group
Group type: COMPARATOR
Intervention: Dome-to-neck ratio without rebleeding
Number of subjects: 1140
Study 32546694 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 31
Study 32546951 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaleidos case for the 2WIN infrared photoscreener
Number of subjects: 162
Study 32546951 — intervention group
Group type: EXPERIMENTAL
Intervention: GoCheck Kids (GCK) with flash-concentrating case for iPhone 7 Plus
Number of subjects: 162
Study 32546951 — intervention group
Group type: COMPARATOR
Intervention: Kaleidos compared to cycloplegic examination
Number of subjects: 162
Study 32547188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosomal docetaxel lipid suspension (NDLS) chemotherapy (75-100 mg/m2)
Number of subjects: 91
Study 32547188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosomal docetaxel lipid suspension (NDLS) chemotherapy
Number of subjects: 91
Study 32547189 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 33
Study 32547210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0
Study 32547424 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-Rigid (WR) cuffs
Number of subjects: 15
Study 32547424 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-Elastic (NE) bands
Number of subjects: 15
Study 32547424 — intervention group
Group type: COMPARATOR
Intervention: No bands (Control)
Number of subjects: 15
Study 32547496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrified blastocyst transfers
Number of subjects: 0
Study 32547496 — intervention group
Group type: COMPARATOR
Intervention: Preparation protocols
Number of subjects: 0
Study 32548285 — intervention group
Group type: EXPERIMENTAL
Intervention: BrICS-LIT platform with semiautomated tumor segmentation algorithms for T2-weighted FLAIR and contrast-enhanced T1-weighted MRI
Number of subjects: 20000
Study 32548285 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 20000
Study 32548677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual Immunotherapy (SLIT)
Number of subjects: 0
Study 32548677 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous Immunotherapy (SCIT)
Number of subjects: 0
Study 32549995 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-session manualised telephone-delivered intervention based on CBT principles plus information about fatigue
Number of subjects: 75
Study 32549995 — intervention group
Group type: COMPARATOR
Intervention: Information only
Number of subjects: 75
Study 32550738 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic (Lidocaine hydrochloride 40 mg plus adrenaline 0.025 mg) with tenaculum replacement
Number of subjects: 228
Study 32550738 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic (Lidocaine hydrochloride 40 mg plus adrenaline 0.025 mg) without tenaculum replacement
Number of subjects: 228
Study 32550738 — intervention group
Group type: COMPARATOR
Intervention: No analgesic with tenaculum replacement
Number of subjects: 228
Study 32550738 — intervention group
Group type: COMPARATOR
Intervention: No analgesic without tenaculum replacement
Number of subjects: 228
Study 32550864 — intervention group
Group type: EXPERIMENTAL
Intervention: GDPT (gemcitabine, cisplatin, prednisone, thalidomide)
Number of subjects: 153
Study 32550864 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 153
Study 32550864 — intervention group
Group type: EXPERIMENTAL
Intervention: GDPT
Number of subjects: 153
Study 32551134 — intervention group
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula surgery
Number of subjects: 54
Study 32551134 — intervention group
Group type: COMPARATOR
Intervention: Arteriovenous graft surgery
Number of subjects: 54
Study 32551134 — intervention group
Group type: EXPERIMENTAL
Intervention: Study-specific assessments
Number of subjects: 54
Study 32551134 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments
Number of subjects: 54
Study 32551134 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength, functional independence, and vascular access satisfaction assessments
Number of subjects: 54
Study 32551439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopic sclerotherapy with long injection needle
Number of subjects: 0
Study 32551439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-assisted endoscopic sclerotherapy with short injection needle
Number of subjects: 0
Study 32551797 — intervention group
Group type: EXPERIMENTAL
Intervention: Okada Purifying Therapy
Number of subjects: 0
Study 32552266 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 4 mg/kg every 4 weeks for ≤48 weeks
Number of subjects: 19
Study 32552278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of health care provider HPV vaccine recommendation
Number of subjects: 955
Study 32552278 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived lack of insurance coverage for the HPV vaccine
Number of subjects: 955
Study 32552299 — intervention group
Group type: EXPERIMENTAL
Intervention: Doll therapy
Number of subjects: 0
Study 32552299 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32552471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 24 months
Number of subjects: 370
Study 32552759 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC)
Number of subjects: 500000
Study 32552763 — intervention group
Group type: EXPERIMENTAL
Intervention: BC-Predict
Number of subjects: 18700
Study 32552763 — intervention group
Group type: COMPARATOR
Intervention: Usual NHSBSP
Number of subjects: 18700
Study 32552775 — intervention group
Group type: EXPERIMENTAL
Intervention: ReWalk ReStore™ soft robotic exosuit
Number of subjects: 44
Study 32552778 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy (NET)
Number of subjects: 0
Study 32552828 — intervention group
Group type: EXPERIMENTAL
Intervention: Long endotracheal tube (LET)
Number of subjects: 20
Study 32552828 — intervention group
Group type: COMPARATOR
Intervention: Aintree intubation catheter (AIC)
Number of subjects: 20
Study 32552833 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of a clinical information system embedded electronic order set for delivering evidence-based best practices.
Number of subjects: 0
Study 32553024 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 0
Study 32553024 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 0
Study 32553027 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32553145 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit consumption
Number of subjects: 0
Study 32553145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no kiwifruit)
Number of subjects: 0
Study 32553149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 1.0 mg oral capsule daily for 12 weeks (after 7-day dose escalation)
Number of subjects: 69
Study 32553254 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 7203
Study 32553333 — intervention group
Group type: EXPERIMENTAL
Intervention: DART (dissection and re-entry techniques) with SI (subintimal) stenting
Number of subjects: 231
Study 32553333 — intervention group
Group type: EXPERIMENTAL
Intervention: DART with SI stenting
Number of subjects: 231
Study 32554135 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (viscosity < 439 cP)
Number of subjects: 33
Study 32554135 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (viscosity > 439 cP)
Number of subjects: 33
Study 32554135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 32554315 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel monotherapy (240 mg/m)
Number of subjects: 42
Study 32554539 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) group
Number of subjects: 144
Study 32554539 — intervention group
Group type: COMPARATOR
Intervention: Non-OSA group
Number of subjects: 144
Study 32554539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination scores at 36 months
Number of subjects: 144
Study 32554609 — intervention group
Group type: EXPERIMENTAL
Intervention: E7046 (125 mg)
Number of subjects: 30
Study 32554609 — intervention group
Group type: EXPERIMENTAL
Intervention: E7046 (250 mg)
Number of subjects: 30
Study 32554609 — intervention group
Group type: EXPERIMENTAL
Intervention: E7046 (500 mg)
Number of subjects: 30
Study 32554609 — intervention group
Group type: EXPERIMENTAL
Intervention: E7046 (750 mg)
Number of subjects: 30
Study 32554609 — intervention group
Group type: EXPERIMENTAL
Intervention: E7046 (all doses)
Number of subjects: 30
Study 32554615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg intravenously every 3 weeks (Q3W) in Group 3 (n=56)
Number of subjects: 115
Study 32554615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg intravenously every 2 weeks (Q2W) in Group 1 (n=59)
Number of subjects: 115
Study 32554615 — intervention group
Group type: COMPARATOR
Intervention: Both groups combined
Number of subjects: 115
Study 32554725 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic questionnaire for symptom monitoring
Number of subjects: 29
Study 32554740 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) using a limited sampling strategy (t=0 and t=5 hours)
Number of subjects: 100
Study 32554740 — intervention group
Group type: COMPARATOR
Intervention: Historical controls without TDM
Number of subjects: 100
Study 32554800 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobar ICH
Number of subjects: 1094
Study 32554800 — intervention group
Group type: COMPARATOR
Intervention: Non-lobar ICH
Number of subjects: 1094
Study 32554854 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain and very long-chain acylcarnitines
Number of subjects: 163
Study 32554854 — intervention group
Group type: EXPERIMENTAL
Intervention: Odd-chain acylcarnitines
Number of subjects: 163
Study 32554854 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosadienoylcarnitine
Number of subjects: 163
Study 32554854 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxystearoylcarnitine
Number of subjects: 163
Study 32554922 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning model (neural network)
Number of subjects: 8980
Study 32554922 — intervention group
Group type: COMPARATOR
Intervention: Traditional spirometry metrics (FEV1/FVC)
Number of subjects: 8980
Study 32554922 — intervention group
Group type: COMPARATOR
Intervention: Traditional spirometry metrics (FEV1% predicted)
Number of subjects: 8980
Study 32554922 — intervention group
Group type: COMPARATOR
Intervention: Random forest classifier
Number of subjects: 8980
Study 32554923 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement inhibitors
Number of subjects: 0
Study 32554923 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0